Wednesday, December 17, 2025 | 02:06 PM ISTहिंदी में पढें
Business Standard
Notification Icon
userprofile IconSearch

Alembic Pharma's Q2 net profit up 35% at Rs 333 cr on strong domestic biz

Consolidated total income up 17.65 per cent at Rs 1,460.32 cr in Q2 of FY21 as against Rs 1.241.23 cr a year ago

cash, currency, notes, funds, investment, shares, growth, profit, loss, tax, money, income, earnings
premium

The company's overall international formulations grew by 21 per cent to stand at Rs 779 crore during the quarter

Vinay Umarji Ahmedabad
Vadodara-based Alembic Pharmaceuticals Limited has registered a 35 per cent growth in its consolidated profit after tax (PAT) for the quarter ended September 30, 2020. As against a net profit of Rs 246.27 crore in Q2 of previous fiscal 2019-20, the company posted a PAT of Rs 333.37 crore in the second quarter of current fiscal 2020-21.

The company's consolidated total income rose by 17.65 per cent to stand at Rs 1,460.32 crore in Q2 of FY21 as against Rs 1.241.23 crore in Q2 of FY'20. 

While Alembic Pharma's international formulations business and active pharmaceutical ingredients (API) business did well during the